Home›Stock Screener›Mercury Laboratories

Mercury Laboratories Share Price Today | Stock Price & Mercury Laboratories Share Screener

MERCURYLAB Pharmaceuticals
Live Share Price BSE
₹780.00
▲ 32.00 (4.28%)
2026-10-05 00:00:00

As of October 5, 2026, the live Mercury Laboratories share price (BSE: MERCURYLAB) is ₹780.00, up 4.28% from the previous close, with shares trading between ₹780.00 and ₹785.00 in today's trading session, and a 52-week range of ₹700.00–₹904.00. Check MERCURYLAB 52-week performance for the annual price range and momentum. Use the Mercury Laboratories stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Mercury Laboratories opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹76 and net income of ₹4, with EBITDA of ₹9, an operating margin of 10.0% and a profit margin of 5.3%.

Mercury Laboratories Market Cap ₹94.10 Cr.
MERCURYLAB P/E Ratio (TTM) 22.59
Mercury Laboratories P/B Ratio 1.62
EPS (TTM) ₹40.28
Dividend Yield 0.45%
Debt to Equity 0.12
MERCURYLAB 52 Week High ₹904.00
Mercury Laboratories 52 Week Low ₹700.00
Operating Margin 10.00%
Profit Margin 5.26%
MERCURYLAB Revenue (TTM) ₹76.00
EBITDA ₹9.00
Net Income ₹4.00
Total Assets ₹79.00
Total Equity ₹58.00

Mercury Laboratories Share Price Chart

Track the current stock price of Mercury Laboratories with an interactive chart. Analyse MERCURYLAB share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Mercury Laboratories stock quote in one place.

The quote of ₹780.00 sits between the 52-week low of ₹700.00 and the 52-week high of ₹904.00, and the latest session moved 4.28% from the previous close.

Mercury Laboratories Company Profile - Fundamental Screener

Screen Mercury Laboratories company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for MERCURYLAB shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE947G01011.

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals
Sub-Sector Pharmaceuticals
Segment E

Identifiers and Leadership

ISIN INE947G01011

Mercury Laboratories Balance Sheet Screener

Screen MERCURYLAB balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹79, up from ₹74 in 2025.

Latest statistics put total assets at ₹79 and shareholder funds at ₹58, with a leverage ratio of 0.12.

Item 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017

Assets

Total Assets 79 74 68 64 62 65 56 57 52 51
Current Assets 45 39 40 40 35 38 32 32 30 32
Fixed Assets 24 25 24 24 26 26 24 24 21 18

Liabilities

Total Liabilities 0 0 0 0 0 0 0 0 0 0
Current Liabilities 9 6 5 4 6 10 9 11 12 10
Non-Current Liabilities 0 0 0 0 0 0 0 0 0 0

Shareholders' Equity

Total Equity 58 54 51 46 40 37 32 29 26 25
Share Capital 1 1 1 1 1 1 1 1 1 1
Reserves & Surplus 57 52 50 44 39 36 31 28 25 23

Mercury Laboratories Income Statement Screener - Profit & Revenue Analysis

Screen Mercury Laboratories income statement and profit fundamentals. Analyze MERCURYLAB quarterly results. Mercury Laboratories reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For None-None, revenue was ₹76 and net profit was ₹4, equal to earnings per unit of ₹34.70, at an operating margin of 10%.

In that period expenses were ₹66, interest cost ₹0 and tax ₹1. The next period listed, 2026-March, shows revenue of ₹78 and net profit of ₹5.

Item None-None 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March 2016-March 2015-March

Revenue and Expenses

Revenue 76 78 76 77 77 59 70 58 57 52 48 48 42
Expenses 66 67 68 67 67 51 59 51 50 48 41 41 35

Operating Costs and Margins

EBITDA 9 11 8 10 10 8 11 7 7 5 7 7 7
Operating Profit % 10.00% 12.00% 9.00% 12.00% 11.00% 12.00% 14.00% 11.00% 10.00% 9.00% 14.00% 14.00% 14.00%
Depreciation 3 3 3 3 3 3 2 2 2 2 1 1 1
Interest 0 1 1 0 0 0 1 1 1 1 1 1 1

Profit and Earnings

Profit Before Tax 5 7 5 7 7 5 8 4 4 3 5 5 5
Tax 1 2 2 1 2 2 3 1 1 0 2 1 1
Net Profit 4 5 3 6 6 4 5 3 3 2 3 4 3
EPS 34.70 40.28 26.21 47.12 46.49 29.68 44.48 26.90 23.63 16.78 22.53 32.69 27.61

Mercury Laboratories Cash Flow Screener - Liquidity Fundamentals

Screen MERCURYLAB cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2026-March, operating activities generated ₹4, and net cash flow was an inflow of ₹4.

Over the same period, investing activities used ₹3 and financing activities provided ₹3.

Item 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March

Cash from Operations and Investing

Operating Activities 4 5 8 3 5 8 6 5 5 2
Investing Activities -3 -9 -6 -1 -2 -5 -1 -5 -4 -2

Financing and Net Cash

Financing Activities 3 -2 -1 -1 -1 -1 -3 -3 1 0
Net Cash Flow 4 -6 1 0 2 2 1 -2 2 0

Mercury Laboratories Shareholding Pattern Screener

See Mercury Laboratories shareholding pattern with promoter, FII, and DII holdings. Check Mercury Laboratories promoter holding and ownership changes for MERCURYLAB on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Mar, promoters held 73.66%, foreign institutions 0.00%, domestic institutions 0.00% and the public 16.58%, spread across 1,316 shareholders.

The shareholder count was 1,316 in 2026-Mar, compared with 1,328 in 2026-Jun.

Item 2026-Mar 2026-Jun 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar 2024-Jun

Promoter Holding

Promoter Holding 73.66% 73.66% 73.66% 73.66% 73.66% 73.66% 73.66% 73.66%

Institutional Investors

FII Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
DII Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 16.58% 16.58% 16.66% 16.66% 16.71% 16.59% 16.86% 16.86%
Other Holding 9.77% 9.76% 9.68% 9.68% 9.63% 9.76% 9.48% 9.48%
Shareholder Count 1,316 1,328 1,397 1,384 1,365 1,321 1,214 1,259

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Mercury Laboratories. Mercury Laboratories dividend yield can be compared with peers and other stocks in the market.

The latest dividend recorded was ₹3.50 per unit for 2026-March, a yield of 0.45%, compared with ₹3.50 for 2025-March.

Dividends are listed for 10 periods, with the three most recent payouts at ₹3.50, ₹3.50 and ₹3.50 per unit.

Period Dividend Per Share Dividend Yield
2026-March ₹3.50 0.45%
2025-March ₹3.50 0.50%
2024-March ₹3.50 0.43%
2023-March ₹3.50 0.42%
2022-March ₹3.50 0.63%
2021-March ₹3.50 0.72%
2020-March ₹2.00 0.31%
2019-March ₹1.50 0.53%
2018-March ₹1.50 0.44%
2017-March ₹1.50 0.38%

Mercury Laboratories Stock Index Membership - Nifty & Sensex

See which indices include Mercury Laboratories stock. Check MERCURYLAB index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

Complete Index List

Mercury Laboratories is not part of any tracked indices.
Only major market indices are tracked in our system.

Mercury Laboratories Market Events Screener - Corporate Actions

Get Mercury Laboratories corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Mercury Laboratories stock events that may affect MERCURYLAB share price, along with derivatives, futures and options activity and sector gainers.

15 corporate actions are listed, the most recent entry being Annual General Meeting dated September 28, 2026, with a record date of September 28, 2026.

It is followed by Dividend dated September 21, 2026 and Quarterly Result Announcement dated July 25, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-09-28 2026-09-28 Annual General Meeting NA 8.60%
2026-09-21 2026-09-21 Dividend ₹ 3.50 /share 1.69%
2026-07-25 2026-07-25 Quarterly Result Announcement NA 4.91%
2026-05-29 2026-05-29 Quarterly Result Announcement NA 3.61%
2026-02-11 2026-02-11 Quarterly Result Announcement NA 2.06%
2025-11-11 2025-11-11 Quarterly Result Announcement NA 2.38%
2025-08-13 2025-08-13 Quarterly Result Announcement NA -6.45%
2025-08-13 2025-08-13 Annual General Meeting NA -4.77%
2025-08-06 2025-08-06 Dividend ₹ 3.50 /share -0.90%
2025-05-14 2025-05-14 Quarterly Result Announcement NA -1.75%
2025-02-12 2025-02-12 Quarterly Result Announcement NA -4.38%
2024-11-14 2024-11-14 Quarterly Result Announcement NA -4.88%
2024-09-27 2024-09-27 Annual General Meeting NA -1.49%
2024-09-20 2024-09-21 Dividend ₹ 3.50 /share 19.51%
2023-09-20 2023-09-21 Dividend ₹ 3.50 /share 25.90%

Mercury Laboratories Competitors Screener - Peer Stocks Comparison

Screen MERCURYLAB competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 444,813 36.44 61,674 12.69% 11,565 40.74
Divis Laboratories 253,841 86.51 11,067 13.95% 2,568 63.87
Torrent Pharmaceuticals 185,791 85.91 13,886 20.34% 2,138 46.50
Zydus Life Science 122,519 26.32 27,658 17.64% 5,026 66.57
Cipla 112,291 33.44 29,045 2.24% 3,870 45.42
Laurus Labs 109,089 99.70 6,868 22.01% 890 64.04
Dr Reddys Laboratories 103,766 32.05 35,059 3.90% 4,158 63.11
Mankind Pharma 100,639 48.73 14,636 14.85% 1,938 55.24
Aurobindo Pharma 97,642 26.36 34,145 5.56% 3,503 54.66
Lupin 94,921 16.99 29,039 26.75% 5,356 35.30

Mercury Laboratories Company Announcements - News & Reports Screener

Screen MERCURYLAB latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated .

The next most recent announcements are dated October 3, 2026 and September 3, 2026.

Date Update Actions
Shareholder Meeting / Postal Ballot-Outcome of AGM -
2026-10-03 Closure of Trading Window -
2026-09-03 Announcement under Regulation 30 (LODR)-Change in Management -
2026-09-02 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-09-01 Reg. 34 (1) Annual Report. -
2026-09-01 Submission Of Notice Of The 45Th Annual General Meeting Of The Company -
2026-08-27 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-08-21 Announcement under Regulation 30 (LODR)-Change in Management -
2026-08-20 Communication To Shareholders - Intimation On Tax Deduction On Dividend -
2026-07-27 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-07-25 Unaudited Financial Results For The Quarter Ended On June 30 2026 -
2026-07-25 Board Meeting Outcome for Outcome Of The Board Meeting Held On July 25 2026 -
2026-07-16 Board Meeting Intimation for Approval Of The Unaudited Financial Results For The Quarter Ended On June 30 2026. -
2026-07-06 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-07-04 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-07-01 Announcement under Regulation 30 (LODR)-Credit Rating -
2026-06-25 Closure of Trading Window -
2026-06-11 Announcement under Regulation 30 (LODR)-Change in Management -
2026-05-31 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-05-29 Corrigendum To Audited Financial Results Of The Company For The Quarter And Financial Year Ended On March 31 2026 -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹780.00, within a 52-week range of ₹700.00 to ₹904.00. The P/E ratio is 22.59 and the P/B ratio is 1.62, with earnings per unit of ₹40.28. Market capitalisation stands at ₹94.10 Cr and the dividend yield is 0.45%. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the BSE. Key statistics were last updated on October 6, 2026. This page covers 10 balance sheet periods, 13 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.